leisure time -WSS

leisure time

author：Wikipedia 2025-09-29 19:58:44 - browse：64618

CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with liver cancer in early clinical data presented Monday at the American Society of Clinical Oncology annual meeting. The study, though preliminary and small with only 24 patients, represents a triad of firsts for one of the trial’s sponsors.

“It’s the first CAR therapy working in liver cancer. First validation of targeting GPC3 as a target. It’s the first validation of our armoring strategy. And it’s the first of many of our visions of CAR therapy in general,” Matt Hellmann, a medical oncologist and early development oncology lead at AstraZeneca, said in an interview.

This abstract, presented by cancer researcher Qi Zhang of Zhejiang University School of Medicine, is yet another significant showing by AstraZeneca at this ASCO. The company had two plenary presentations on its blockbuster lung cancer drug Tagrisso and immunotherapy drug Imfinzi — as well as new results on Enhertu, which AstraZeneca developed with Daiichi Sankyo.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： FDA cancer chief on how to get things done: ‘Don’t tell anybody'

explore

leisure time

WSS

Carbon Health diabetes program, a test of data

Food as medicine: Medically tailored meals may get standardized

Readout Newsletter: Merck, Vertex, and Viking updates

Weight loss drugs should be covered by insurers, AMA says

Ohio still needs to do more to protect the right to abortion

Healthy food access boosts outcomes in two studies

knowledge

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Wildfire smoke exposes gaps in outdoor worker protections

How state and local governments are sidelining science

Peter Hotez and the public health issue of online harassment

After decades in use, heart stents finally beat placebo

Medical records are filled with copy

Supreme Court mifepristone arguments center on docs' right to sue

Peter Hotez and the public health issue of online harassment

States should stop sabotaging methadone treatment reform

Malaria cases in Florida and Texas: Here’s what you need to know

Study says nonprofit hospitals fall short in charity care spending

entertainment

Washington mulls new rules to avert another Change Healthcare

NIH chief: government has fallen behind pharma on clinical trials

Cancer diagnosis changes perspective doctor, former hospital CEO

Supreme Court mifepristone arguments center on docs' right to sue

Readout Newsletter: Zepbound, Valneva's vaccine, and more

Abortion pill case raises question: who can sue the FDA?

explore

leisure time

hotspot

hotspot